Aggrenox Mechanism Of Action

2 Replies Updated

Conversation Starter

Ravindra Says:

Please let me know the rational for the use of aspirin and dipyridamole.
I am intersested in MOA (mechanism of action for aggrenox) OF AGGRENOX.
* * Edited by Site Admin 6/9/2005 11:23:12 AM PDT * *

Showing Replies 1 - 2 of 2 RSS Feed

of 1    
MD PT Tom Says:

Is this the information you were looking for?

Mechanism of Action
The antithrombotic action of AGGRENOX (aspirin/extended-release dipyridamole) is the result of the additive antiplatelet effects of dipyridamole and aspirin.

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5-1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).

Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).

Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction.

There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their coadministration as AGGRENOX.

Absorption: Peak plasma levels of dipyridamole are achieved 2 hours (range 1-6 hours) after administration of a daily dose of 400 mg AGGRENOX (given as 200 mg b.i.d.). The peak plasma concentration at steady-state is 1.98 µg/mL (1.01-3.99 µg/mL) and the steady-state trough concentration is 0.53 µg/mL (0.18-1.01µg/mL).

Effect of Food: When AGGRENOX capsules were taken with a high fat meal, dipyridamole peak plasma levels (Cmax) and total absorption (AUC) were decreased at steady-state by 20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.

Distribution: Dipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.

Metabolism and Elimination: Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase ëz with a half-life of about 15.5 hours. Due to the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with AGGRENOX which, in trial 9.123 was 13.6 hours.

Was this helpful?     0     0  
aggrenox Says:

i found a moa under this link:


anima res - 3d computeranimation

Was this helpful?     0     0  

Viewing page 1 of 1     Reply

More Discussions:

mechanism of action of zinc
What is the mechanism of action of Zinc in the treatment of childhood Diarrhoea? ## Deficiencies in Zinc which is a vita... 3 replies
mechanism of action of hnbb
thanks for this ## we need copy for our drug study ## ## all about hnbb... 3 replies
Mechanism Of Action Ambroxol
mechanism of action of ambroxol ## The mechanism of action of ambroxol and its pharmacokinetics and pharmacodynamics ## ... 2 replies
mechanism of action of doxophyllin
can u pls forward me mechanism of action of doxophyllin ## This is a drug sold in Canada and other countries, used as a ... 2 replies
mechanism of action ## Mechanism Of Action of Difur ## this site is useless... 2 replies
mechanism of action of cyproheptadine hydrochloride sorbitol solution
how does cyproheptadine hydrochloride and sorbitol function in humanbody? And what's the indication of this very med... 1 reply
Mechanism Of Action Montelukast
tried combination of montelukast and levocetrizine in wound healing. in allergies hw does it act? what are the side effe... 1 reply
mechanism of action of salbutamol guaifenesin
i waqnt to know the indications of guaifenesin salbutamol. ## mechanism of salbutamol ang guifenesin... 1 reply
mechanism of action for Balanced Multiple Maintenance Solution With 5 Dextrose
thank u so much. ## This is really something that can be given via IV for many different reasons, such as treating or pr... 1 reply
Mechanism Of Action Erceflora
contarindications of erceflora ## Erceflora is a form of bacillus clausii, it is a bacterium that in some countries is u... 1 reply

Post a Reply

No registration needed.
Simply fill out the form below.



 Optional, stays hidden.
Get notified when a reply is posted here.

4) Text Verification: *
Prevents SPAM.

Show Verification Text

with the privacy policy (20191231).

This form will be submitted securely
Privacy policy cookies information


Discussion Thread Guidelines: Any participation in the discussion threads signifies your agreement with the Terms of Use and Privacy Policy. (1) Act civilized and be respectful towards others. No profanity, vulgarity or lewd / suggestive content is allowed. (2) Posts encouraging, facilitating, or seeking advice about the abuse of medications or other substances are prohibited. (3) Personal contact information (such as telephone numbers, email addresses, etc) is not allowed to appear on our discussion threads. (4) We do not allow our forums to be used for buying, selling, trading, or for the promotion of a product or service. (5) Posting external links to other web sites is not allowed without our prior approval. (6) We reserve the right to edit or remove content which we find objectionable to the community at our sole discretion.

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 January 2009.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA